Rigel Pharmaceuticals
RIGL
135 hedge funds and large institutions have $157M invested in Rigel Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 36 increasing their positions, 51 reducing their positions, and 34 closing their positions.
103% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $584K
0.19% more ownership
Funds ownership: 7.9% → 8.09% (+0.19%)
18% less funds holding
Funds holding: 164 → 135 (-29)
29% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 51
61% less capital invested
Capital invested by funds: $406M → $157M (-$249M)
74% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 34
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$33M |
| 2 |
D.E. Shaw & Co
New York
|
+$5.91M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$5.07M |
| 4 |
Citigroup
New York
|
+$2.96M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$14.7M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$13.2M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$12M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$9.82M |
| 5 |
Millennium Management
New York
|
-$3.76M |
RIGL Hedge Fund Activity: Q2 2022 in Review
135 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2022, worth a combined $157M — down 61% from $406M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of RIGL and 9 opened new positions — a net loss of 25 holders — while 51 trimmed existing stakes and 36 added.
The largest buyer was State Street, adding an estimated $33M. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $14.7M sold.
- 135 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2022, down from 164 in Q1 2022.
- Funds reported $157M of Rigel Pharmaceuticals stock for Q2 2022, down 61% quarter-over-quarter.
- 9 funds opened new Rigel Pharmaceuticals positions in Q2 2022 and 34 closed out, a net change of -25 holders.
- The largest Rigel Pharmaceuticals buyer in Q2 2022 was State Street, an estimated $33M added.
- The largest Rigel Pharmaceuticals seller in Q2 2022 was Rock Springs Capital Management, an estimated $14.7M sold.
Based on aggregated 13F filings for Q2 2022.